A Multicenter, Randomized, Double-Blind, Controlled Phase 3, Efficacy And Safety Study Of Sunitinib (SU011248) In Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Treated With Erlotinib

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Overall Survival (OS)

Outcome Description:

Overall survival is the duration from assignment to study medication to death. For participants who are alive, overall survival is censored at the last contact.

Outcome Time Frame:

Baseline to death or 28 days after last dose for the last participant

Safety Issue:

No

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A6181087

NCT ID:

NCT00457392

Start Date:

July 2007

Completion Date:

December 2012

Related Keywords:

• Carcinoma, Non-Small Cell Lung
• Non-small cell lung cancer
• sunitinib
• erlotinib
• Phase 3
• Carcinoma
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms